{"ticker": {"uuid": "0dc5170b-e789-413d-a9d9-50a37ace21ca", "symbol": "VVOS", "name": "Vivos Therapeutics\u00a0Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Medical Devices"}, "articles": [{"title": "Investor group takes 19.9% position in Vivos Therapeutics (VVOS)", "summary": "An investor group, including V-CO Investors LLC and Michael C. Skaff, has reported a 19.9% beneficial ownership stake in Vivos Therapeutics, Inc. (VVOS), totaling 2,783,102 common shares. This position stems from a $1.6 million subscription by V-Co 4, which included the conversio", "url": "https://www.stocktitan.net/sec-filings/VVOS/schedule-13d-vivos-therapeutics-inc-major-shareholder-acquisition-5-e81518d2dc47.html", "source_name": "Stock Titan", "published_at": "2026-07-16T21:20:29", "published_display": "16 Jul 2026 21:20", "sentiment": "positive", "sentiment_pct": 61, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivos Therapeutics (NASDAQ: VVOS) insider entity buys 5.5M derivatives", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxOOC1oVWtGeWJkSzhVaWlNa0ZGeEZJWXRvTGZZVDRINms0SjJoOG1RLWpuUmU5V0dCTFNmUG5MS0VDWDN4dHpqZ0czZmNQeDRaOF9vYjcyem5BNXcydHduX2dSa0c0YS1zMVdMTWlla21TM3dXcTA5M2xRTHVBeWUzTl9lYlNITzVsVmdkZG0xZllDWUhaRVZWZ2MyUXR2cTVYdTY2eG52VGNsMGtrM3NqR2ZJYWJjTkU?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-15T20:24:16+00:00", "published_display": "15 Jul 2026 20:24", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Michael C. Skaff Discloses Investment at Vivos Therapeutics with 19.9% Stake", "summary": "Michael C. Skaff, through SP Manager LLC and its V-Co investment vehicles, has disclosed a 19.9% beneficial ownership stake in Vivos Therapeutics, Inc. This investment, formalized in a Schedule 13D filing, stems from a private placement in June 2026 that included convertible pref", "url": "https://www.tradingview.com/news/tradingview:0b986cf523702:0-michael-c-skaff-discloses-investment-at-vivos-therapeutics-with-19-9-stake/", "source_name": "TradingView", "published_at": "2026-07-15T21:20:29", "published_display": "15 Jul 2026 21:20", "sentiment": "positive", "sentiment_pct": 60, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivos Therapeutics (NASDAQ: VVOS) holder discloses warrant and preferred stake", "summary": "V-Co Investors 4 LLC, a 10% owner of Vivos Therapeutics (NASDAQ: VVOS), has disclosed its initial beneficial ownership of a Common Stock Purchase Warrant and Series A Convertible Preferred Stock. Both securities are convertible into 2,749,330 common shares at an exercise/conversi", "url": "https://www.stocktitan.net/sec-filings/VVOS/form-3-vivos-therapeutics-inc-initial-statement-of-beneficial-ownersh-e03df6f8681e.html", "source_name": "Stock Titan", "published_at": "2026-07-15T20:20:29", "published_display": "15 Jul 2026 20:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Vivos Therapeutics Inc For: 15 July By Investing.com", "summary": "This article from Investing.com reports on a Form 4 filing for Vivos Therapeutics Inc on July 15. Form 4 filings disclose changes in beneficial ownership of a company's securities by insiders. The article provides the title and source, indicating it's a routine financial disclosu", "url": "https://ca.investing.com/news/stock-market-news/form-4-vivos-therapeuticsinc-for-15-july-93CH-4736099", "source_name": "Investing.com Canada", "published_at": "2026-07-15T20:20:29", "published_display": "15 Jul 2026 20:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivos Therapeutics Inc. (VVOS) Stock Price | Live Quotes & Charts | NASDAQ", "summary": "This page provides live quotes and charts for Vivos Therapeutics Inc. (VVOS), currently trading at $0.4178 with a slight decrease. It notes that there are no current analyst ratings or earnings information available for the company. The page is part of a trading education platfor", "url": "https://www.timothysykes.com/quote/VVOS/", "source_name": "www.timothysykes.com", "published_at": "2026-07-15T00:20:29", "published_display": "15 Jul 2026 00:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Reflecting On Medical Devices & Supplies - Specialty Stocks\u2019 Q1 Earnings: Integer Holdings (NYSE:ITGR)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNUFd1SUpRcWlCdEFjU1YzNTZkdjBfRkwyY2lBYjh1ZXZlZTlyVlpWSWx1bExvckFrNHNhUEdVTGNFWUxaMkVDZUV2c2hPS1h2YVhNSHNsVzFYNUFrNHBnRVM1STRsa2Zmb0VXeEQ4UFRGNDBOWXZfWVU5VFUyQ3JZZm9KamZMWXVDSEtNMWwyVktpaEZfRjVNU1BYaWJ3NnpNUmRyMEpsSzBXdw?oc=5", "source_name": "Market source", "published_at": "2026-07-14T18:07:11+00:00", "published_display": "14 Jul 2026 18:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Price to earnings forward of Vivos Therapeutics, Inc. \u2013 NASDAQ:VVOS", "summary": "This article displays financial information for Vivos Therapeutics, Inc. (NASDAQ: VVOS), specifically focusing on its price-to-earnings forward ratio. The content appears to be a stub or a section of a larger financial data platform, showing basic company identification and navig", "url": "https://www.tradingview.com/symbols/NASDAQ-VVOS/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-09T23:39:30", "published_display": "09 Jul 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivos Therapeutics Raises $2.1 Million in PIPE With V-Co 4 and Bigger Capital", "summary": "Vivos Therapeutics completed a $2.1 million private placement (PIPE) with V-Co Investors 4 and Bigger Capital Fund, involving Series A Convertible Preferred Stock and warrants. The company received $1.0 million in cash, with another $1.0 million from a converted bridge note. Vivo", "url": "https://www.tradingview.com/news/tradingview:26dcce57228c3:0-vivos-therapeutics-raises-2-1-million-in-pipe-with-v-co-4-and-bigger-capital/", "source_name": "TradingView", "published_at": "2026-07-08T10:39:18", "published_display": "08 Jul 2026 10:39", "sentiment": "positive", "sentiment_pct": 73, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivos Therapeutics (VVOS) completes $2.1M PIPE with preferred stock and warrants", "summary": "Vivos Therapeutics completed a private PIPE financing on June 30, 2026, raising approximately $2.1 million. The financing involved selling units consisting of Series A Convertible Preferred Stock, five-year warrants at an exercise price of $0.456, and contingent subscription righ", "url": "https://www.stocktitan.net/sec-filings/VVOS/8-k-vivos-therapeutics-inc-reports-material-event-1be228ee9bc9.html", "source_name": "Stock Titan", "published_at": "2026-07-07T21:30:28", "published_display": "07 Jul 2026 21:30", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VVOS - Vivos Therapeutics Inc Latest SEC Filings", "summary": "This article provides the latest SEC filing information for Vivos Therapeutics Inc (VVOS). It includes key financial metrics such as market cap, enterprise value, income, sales, and various ratios. The data also covers stock performance, insider and institutional ownership, and a", "url": "https://finviz.com/stock?t=VVOS&ta=1&p=w&ty=lf&page=5", "source_name": "Finviz", "published_at": "2026-07-06T10:10:39", "published_display": "06 Jul 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Vivos Therapeutics, Inc. \u2013 NASDAQ:VVOS", "summary": "The article focuses on the enterprise value to EBITDA forward for Vivos Therapeutics, Inc. (NASDAQ:VVOS). It appears to be a financial data point presented within the TradingView platform for the company's NASDAQ listing.", "url": "https://www.tradingview.com/symbols/NASDAQ-VVOS/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T04:40:27", "published_display": "06 Jul 2026 04:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivos Therapeutics (VVOS) Stock Sees Fair Value Moves Lower As Analysts Reset Growth Assumptions", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxNNVVpQW1DWTczb3YtNFgwV09ReWdfQk4td09zV2xCY1hTc1hFVER3NEdDVzh5MlFzZnFGQnNNaGJ3RmhFVndQUGlYZ1hNdWxQMzdtRkNhT1VWeW5iTTJJSGJsbzFBSkc1UWFTVVIwUGtHeW1mYk5LR2pCeWlZOURSX2dDRm1oeVpJQ01UY2IyQW1JRy0tZHRrVEQxZU94bjc3?oc=5", "source_name": "Market source", "published_at": "2026-07-03T07:00:00+00:00", "published_display": "03 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "12 Health Care Stocks Moving In Tuesday's After-Market Session", "summary": "This article lists 12 healthcare stocks that experienced significant movement in Tuesday's after-market trading session. It details both gainers and losers, including Alzamend Neuro, Vivos Therapeutics, Advanced Biomed, Aclaris Therapeutics, NexGel, and Aethlon Medical as gainers", "url": "https://www.benzinga.com/trading-ideas/movers/26/06/60205064/12-health-care-stocks-moving-tuesday-s-after-market-session", "source_name": "Benzinga", "published_at": "2026-07-01T07:39:20", "published_display": "01 Jul 2026 07:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivos says its Vida appliance improved insomnia in all 37 patients", "summary": "Vivos Therapeutics announced compelling clinical data for its FDA-cleared Vida\u00ae oral appliance, showing statistically significant improvement in insomnia severity in all 37 study participants. The appliance, which reduced Insomnia Severity Index scores by an average of 65%, is al", "url": "https://www.stocktitan.net/news/VVOS/vivos-vida-appliance-shows-statistically-significant-improvement-in-h3s2rd7co3f4.html", "source_name": "Stock Titan", "published_at": "2026-06-30T20:39:57", "published_display": "30 Jun 2026 20:39", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivos\u2019 Vida\u00ae Appliance Shows Statistically Significant Improvement in Insomnia Severity in 100% of Study Participants", "summary": "Vivos Therapeutics announced that its FDA-cleared Vida\u00ae oral appliance demonstrated statistically significant improvement in insomnia severity for 100% of participants in a recent clinical study. The study, involving 37 adult patients with moderate to severe insomnia, showed an a", "url": "https://sg.finance.yahoo.com/news/vivos-vida-appliance-shows-statistically-124500026.html", "source_name": "Market source", "published_at": "2026-06-30T13:10:58", "published_display": "30 Jun 2026 13:10", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivos Therapeutics, Inc. Actuals & Estimates (NASDAQ:VVOS)", "summary": "This article provides an overview of Vivos Therapeutics, Inc. (NASDAQ:VVOS) stock performance, financial data, and analyst estimates. Key figures include the current stock price, recent declines, future price forecasts from analysts, historical highs and lows, market capitalizati", "url": "https://www.tradingview.com/symbols/NASDAQ-VVOS/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T00:10:27", "published_display": "26 Jun 2026 00:10", "sentiment": "negative", "sentiment_pct": 38, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivos (NASDAQ: VVOS) extends Streeterville $4.5M debt-for-equity pact", "summary": "Vivos Therapeutics has extended its debt-for-equity agreement with Streeterville Capital, pushing the deadline for a $2.6 million equity financing to August 31, 2026. This extension gives Vivos more time to raise capital, with Streeterville reaffirming its commitment to convert u", "url": "https://www.stocktitan.net/sec-filings/VVOS/8-k-vivos-therapeutics-inc-reports-material-event-a3c265231026.html", "source_name": "Stock Titan", "published_at": "2026-06-25T21:10:25", "published_display": "25 Jun 2026 21:10", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivos Therapeutics Enters Debt-for-Equity Deal, Extends $2.6M Financing Deadline With Streeterville", "summary": "Vivos Therapeutics has entered into a debt-for-equity Exchange Agreement with Streeterville Capital to convert debt into stock, aiming to reduce leverage and improve liquidity. Additionally, the deadline for completing a $2.6 million financing was extended to August 31, 2026, pro", "url": "https://www.tradingview.com/news/tradingview:392a2bbaa4f3f:0-vivos-therapeutics-enters-debt-for-equity-deal-extends-2-6m-financing-deadline-with-streeterville/", "source_name": "TradingView", "published_at": "2026-06-25T21:10:25", "published_display": "25 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VVOS Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for Vivos Therapeutics, Inc. (VVOS) stock, including analyst ratings, historical performance, and financial data. It indicates a significant decrease in stock price over the past year and presents analyst price estimates for the f", "url": "https://www.tradingview.com/symbols/NASDAQ-VVOS/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T16:10:26", "published_display": "25 Jun 2026 16:10", "sentiment": "negative", "sentiment_pct": 37, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivos Therapeutics and Streeterville Extend Timeframe of Strategic Financing Agreement and Reaffirm Commitment to Convert Debt Into Common Stock and Perpetual Preferred Equity", "summary": "Vivos Therapeutics and Streeterville Capital, LLC have extended their strategic financing agreement through August 31, 2026. This extension allows Vivos Therapeutics more time to complete its capital-raising requirements. Streeterville reaffirmed its commitment to convert up to $", "url": "https://finance.yahoo.com/healthcare/articles/vivos-therapeutics-streeterville-extend-timeframe-123000802.html", "source_name": "Market source", "published_at": "2026-06-25T12:40:54", "published_display": "25 Jun 2026 12:40", "sentiment": "positive", "sentiment_pct": 62, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Vivos Therapeutics and Streeterville Extend Timeframe of Strategic Financing Agreement and Reaffirm Commitment to Convert Debt Into Common Stock and Perpetual Preferred Equity", "summary": "Vivos Therapeutics and Streeterville Capital have extended the timeframe of their strategic financing agreement. This extension reaffirms their commitment to converting Streeterville's existing debt into Vivos common stock and perpetual preferred equity. The agreement aims to sig", "url": "https://www.moomoo.com/hans/news/post/71829847/press-release-vivos-therapeutics-and-streeterville-extend-timeframe-of-strategic?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-06-23T05:10:25", "published_display": "23 Jun 2026 05:10", "sentiment": "positive", "sentiment_pct": 64, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivos Therapeutics Extends Financing Agreement With Streeterville Through August", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/vivos-therapeutics-extends-financing-agreement-132301980.html", "source_name": "MT Newswires", "published_at": "2026-06-22T13:23:01+00:00", "published_display": "22 Jun 2026 13:23", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivos extends debt conversion deadline with Streeterville to August", "summary": "Vivos Therapeutics Inc. has extended its debt conversion agreement with Streeterville Capital, LLC until August 31, 2026. This extension allows Vivos more time to raise $2.6 million in equity, after which Streeterville will convert up to $4.5 million in outstanding debt into perp", "url": "https://www.investing.com/news/company-news/vivos-extends-debt-conversion-deadline-with-streeterville-to-august-93CH-4752742", "source_name": "Investing.com", "published_at": "2026-06-22T12:41:00", "published_display": "22 Jun 2026 12:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivos extends debt conversion deadline with Streeterville to August By Investing.com", "summary": "Vivos Therapeutics Inc. has extended its debt conversion deadline with Streeterville Capital, LLC to August 31, 2026. This extension allows Vivos more time to complete a planned equity raise and rights offering, aiming to strengthen its stockholders' equity and maintain Nasdaq li", "url": "https://ca.investing.com/news/stock-market-news/vivos-extends-debt-conversion-deadline-with-streeterville-to-august-93CH-4700882", "source_name": "Investing.com Canada", "published_at": "2026-06-22T12:40:27", "published_display": "22 Jun 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivos gets more time to convert $4.5M debt into equity", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxORnFvTHJCb2ZtX1pRS2pMc0U4Ql9paWdkWFM2SlhCa1lFM0RNU1Q4X0VJZW1HbDlXYUthRE11V2RZMXQ0bTJJVWM4RHhOejBqamtUelVFeGZCNWpPM1k1dU16YnRfUmtUVHZoWnBEbzJVSUt5cWJnY3VvMFl3aE91OG1MdzM4eFlhRy0ybzNFeUs5OXByUGcwX1lrM2tpSHhpdi03ajQ3cWdBZ1dZYl95eHdzVnhDZjROV19uMEhB?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivos Therapeutics Inc (VVOS) Institutional Confidence", "summary": "This article from TradingKey provides an overview of institutional confidence in Vivos Therapeutics Inc (VVOS). It presents a table of institutional shareholdings, detailing the number of shares held by various entities like V-CO Investors, L.L.C. and Armistice Capital LLC, and h", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-vvos/sentiment", "source_name": "TradingKey", "published_at": "2026-06-19T06:10:44", "published_display": "19 Jun 2026 06:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivos Therapeutics Inc (VVOS) Valuation: PE, PB & Fair Value Analysis", "summary": "Vivos Therapeutics Inc (VVOS) currently holds a valuation score of 9.29, placing it 23rd out of 203 companies in the Healthcare Equipment & Supplies industry. The company's P/E ratio is -0.23, which is significantly below its recent high and above its recent low. However, key val", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-vvos/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-19T06:10:44", "published_display": "19 Jun 2026 06:10", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivos Therapeutics Inc (VVOS) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "The article provides a historical overview of dividend payouts and stock splits for Vivos Therapeutics Inc (VVOS). It indicates that the company has distributed no dividends over the past five years and details multiple 25-to-1 merger-related stock splits that occurred on October", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-vvos/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T17:09:33", "published_display": "18 Jun 2026 17:09", "sentiment": "negative", "sentiment_pct": 41, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivos Therapeutics Inc (VVOS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a detailed revenue breakdown for Vivos Therapeutics Inc (VVOS) as of April 6, covering its business segments. Key revenue contributors include sleep testing services, appliance sales to integrated providers, and center revenue. The data presented reflects fi", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-vvos/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T16:09:33", "published_display": "18 Jun 2026 16:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivos Therapeutics (NASDAQ: VVOS) outlines proposed tradable rights offering terms", "summary": "Vivos Therapeutics plans a tradable rights offering to raise capital for operations, intending to distribute transferable subscription rights to shareholders as a dividend. The proposed terms indicate an initial exercise price for common shares at the greater of $1.25 or 20% abov", "url": "https://www.stocktitan.net/sec-filings/VVOS/8-k-vivos-therapeutics-inc-reports-material-event-f09acd67f14c.html", "source_name": "Stock Titan", "published_at": "2026-06-16T21:09:57", "published_display": "16 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivos Therapeutics Partners with Florida Cardiology Group to Expand Sleep Apnea and Insomnia Treatment for Cardiovascular Patients", "summary": "Vivos Therapeutics, Inc. has announced a strategic collaboration with South Palm Cardiovascular Associates, a multi-location Florida cardiology practice, to form AIM Florida, LLC. This partnership aims to integrate diagnostic and therapeutic clinical treatment services for cardio", "url": "https://www.minichart.com.sg/2026/06/16/vivos-therapeutics-partners-with-florida-cardiology-group-to-expand-sleep-apnea-and-insomnia-treatment-for-cardiovascular-patients/", "source_name": "Minichart", "published_at": "2026-06-16T12:10:00", "published_display": "16 Jun 2026 12:10", "sentiment": "positive", "sentiment_pct": 77, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivos Therapeutics (NASDAQ: VVOS) inks AIM Florida deal with major cardiology group", "summary": "Vivos Therapeutics (NASDAQ: VVOS) has partnered with South Palm Cardiovascular Associates (SPCVA) to establish AIM Florida, a management services organization focused on providing sleep apnea and insomnia care to cardiovascular patients in Florida. Vivos expects to hold at least ", "url": "https://www.stocktitan.net/sec-filings/VVOS/8-k-vivos-therapeutics-inc-reports-material-event-3a8dfac892b7.html", "source_name": "Stock Titan", "published_at": "2026-06-16T00:09:30", "published_display": "16 Jun 2026 00:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks Q1 Earnings: ICU Medical (NASDAQ:ICUI) Firing on All Cylinders", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAJBVV95cUxQLWl0NWl5MFJhUXFSN0pzSW1sVzJVb21XVml0X0doQnd5eDVUQmVqeFZWSmNmdlZaV2pfbFk3UEl3RXlqZ05pckozR0dnNHNEUlpTa2FPYWc1Z3Q0Y2tXYTljZUlQRkVZNzY2Sl9yRksyUDJkNVQzSTBuLW9uMnI5bzBfTTJGdDUzd25DN3dDSmhwWnpGVXZRVVM2Uy1zMnp4STZ1RGdZZkRpZ21Pb2xtWjRSTk1kc2JrT28wTG81NDV1M2tWaVdrOXBQdVZSTExiTVEzMXpqRnJWWi0xcEdMYVFILXZXbXZVZl9GRm12aTl5OGk4X1dSVjVyU2FIVFpubk1YNm5fQll0MVZqRTZpTA?oc=5", "source_name": "StockStory", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Vivos Therapeutics Plans to File for Proposed Rights Offering", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/vivos-therapeutics-plans-file-proposed-131126815.html", "source_name": "MT Newswires", "published_at": "2026-06-11T13:11:26+00:00", "published_display": "11 Jun 2026 13:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivos Therapeutics Announces Intent to File a Registration Statement for a Proposed Rights Offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQMERQMHJYeFhWS1ItSHhRcUxWeHhSTzF0aXZTQjFUbjNkLWtybHVQSlA4Vzh3bGFxOHdmbEVoN3dSMjlGNEdSazFBRWJoWUJQNDhoeFYxaGUwSUFsS0lNaUJEWV9mQW1rQ0ZjdENEejJWeUVuTGlNYUp4VXpnWmYxQlM2S2tESUk5WWNjNE5Uc3cwVXBwRndkdXBFcThCeDFqLUxhaVd1X1U?oc=5", "source_name": "Market source", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivos Therapeutics Enters Collaboration With Florida Firm to Treat Cardiovascular Patients", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/vivos-therapeutics-enters-collaboration-florida-133851968.html", "source_name": "MT Newswires", "published_at": "2026-06-10T13:38:51+00:00", "published_display": "10 Jun 2026 13:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivos Therapeutics Announces Key Collaboration Agreement with Multi-Location Florida Cardiology Group to Extend Much Needed Sleep Apnea and Insomnia Diagnosis and Treatment to Cardiovascular Patients", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/vivos-therapeutics-announces-key-collaboration-130300275.html", "source_name": "GlobeNewswire", "published_at": "2026-06-10T13:03:00+00:00", "published_display": "10 Jun 2026 13:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivos Therapeutics To Participate in the Small Cap Showcase & WTR Insights on June 9, 2026", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/vivos-therapeutics-participate-small-cap-173900683.html", "source_name": "GlobeNewswire", "published_at": "2026-06-08T17:39:00+00:00", "published_display": "08 Jun 2026 17:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sleep apnea-focused Vivos CEO to present at NYC investor forum", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxNUTlHeU1HMVhxdHV2bld5cUJGZm10VXpCb3hDaDFTM3U4aHBBMnFpUlYxeFJYNm5laTJXc0I3OTJNXzJaS3RLMkJpQm56VVpTVjZyS3RQMUItRlhZamN6b0hacUVMdVBpWnQyWkxYeElpQTBseU9iYVVLcHltdy1mX3h1SGxBZTNwSGRRM2JaQ0xGbWdDclB6OThvRVpCMmM3LVV1eS1vRWVuampkVzZEUC1sNTc1WUJUNEE?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Review: Medical Devices & Supplies - Diversified Stocks Led by Baxter (NYSE:BAX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNYjhBT3BjMWFVU1FFUUFub0d6QUVEUTdwWFVMRG5fN2dHSnIxTXQwMWU1aElKaEV1a2dYLTFHMlBzMVFTZEtaX0xRRDFhZDl1WFdDYWF2RDZxOG9SRUtycmZacTRzM2FaaEU3OS1GZ2taLWtSMjZ4enhVNHRvdzJsanp4cEhNcGI1dllTOUplWUUtNjRlRm85MlFEVWxSYUV2d243QVd3?oc=5", "source_name": "Market source", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Medical Devices & Supplies - Specialty Q4 Earnings: Globus Medical (NYSE:GMED) is the Best in the Biz", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNcDFMNmtOVk5PVFM1YzMyVWhyS3dwY0dMVE5BUng5U1JoOFRQMXNFRGxTMmlBRUV0bENRSWFXTDFZOXBQQkNZT0FOWDdISjRCcU9pRV9aNHBwUVBuZkVEV3g1dklVY19KOE9iWUNpNUtMS2NuOEcxMlQtNU8ydURybEdkNVoxZThWLTBIeVhid2NjQ0FWWTUzb2dxcmlMQThFQmZ4bldzRjcwUQ?oc=5", "source_name": "Market source", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Vivos grows on sleep apnea services, but operating loss hits $19.9M", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxOdFlVeUJmS2ZsaWYzTXJsOEZOd2VlWFByM0lZdFZxaERhZjBBeHFkSEN6Tmh5RmVTcGhxeE9rb3JWOWJzX01qS25vV2dDSTRNdHpHdW9KZFJZZlU1UHh2R1dfb1RNQkdxV2dfLVZ2RS1RTkVTRVlkd1dVYWoxN2JmQ2lLSmREWnpjb3loT2VKbVJlMzJVa0ZSdDh1TGRkZ1FHZkdwWVI3eWtRZw?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-15T07:00:00+00:00", "published_display": "15 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Medical Devices & Supplies - Imaging, Diagnostics Stocks\u2019 Q4 Earnings: Hologic (NASDAQ:HOLX) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOdkl6Ym5HSGVhZUw3TzNlNVFPSjdDQk5NMTVSRW1xVnh3RE5RNU9veVR0TDEtcVdxV3BYelI0bWxCYXgwWmhZQ3ZONUVRdlhjX0ZiMklRVDJQRXN0LXcyVWVnb0E2WTdiRERtZk1pNGpmVHhWbHl5eHJuNnBtTDVPMUluTmRsQUVqYjNlSl8zR3djclh0X2ZIc1gzTlhPanR6ZTJ6R1FB?oc=5", "source_name": "Market source", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Artivion (NYSE:AORT) Vs The Rest Of The Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPaTgxS3dlMlZ5dDZ3dFlGdG9yRWFubkVqMk9yOTN6OEtyemljTWJGYUcxb2pmd2FTNTFKMlhIVGxrdlJsOG5iY1VQaXE4ZmYycTVpRkE0aEJ3QlB5bC10ZXN2dTFYNy0wRWdrNURVUlo5dEMzQklxQ0kwQTRkOXE0UDdTMkRGRWxoQ1ZQeG4tOXNONlR2SkxfZW5ST1B6N3BBeFZZQ3N1UFE?oc=5", "source_name": "Market source", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: CooperCompanies (NASDAQ:COO) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxOellVLTAtRXF1dTFacmVLUmptUVpDSkxGX0MtY2hCY2l3ajU4M25SMG95OHdlc1RHN1dmaHZZMF9uQ0o3R1FBa0NzQUtZMjIzMjU1bmttbGZsZUplQkd5Vmd2NEJoQ0NnbVhmVXppdWhiQkdpcGpQVFJVSHRBXy1pbnFJbXI0R2w3MmlvMEdCY2dGYVE4cWY2MENmeEp1ME9mZEFqSDVtdThTMk9kbUhIdXMtR0k?oc=5", "source_name": "Market source", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q4 Earnings: Integer Holdings (NYSE:ITGR) In The Context Of Other Medical Devices & Supplies - Specialty Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAJBVV95cUxNdFRrRlJvM3J3cGJnVEJ6ZndqMnQxWkE4Wm8zTGtPTVc0OTlLN1pwNXIyclNJMFZkcG5qQTRTWThmNm9WN0hKYXBja3N3Y20zSlkxc2JaQlpYTnAyWnpvUVBvR1JWNmVxZGhSYVlYQklMd01GeFBVNGJWOFBWYUkwYmRrM2xrSktiQWpfTkZtNG1HWThNT0tqLUpYek5qcnFWMGE0QV9CaElrMUpfTEhnOC1pS2t1bkE2VVJHdEhWdEtoX2xKNE1MWk1OSlBSNTVZVU83WEpnb3E4aURwQ3ZyZUFDbndpTTZEa0lZRTJvU2VuTDhreXdCQ25iV3Y4YWxENm1xYQ?oc=5", "source_name": "StockStory", "published_at": "2026-03-16T07:00:00+00:00", "published_display": "16 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highs And Lows: Abbott Laboratories (NYSE:ABT) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxPeVpVN2I3X3lJNXd3TXJmRWV4X0RvRDdYR3l5a1k1SjMxUlhsWHdrUUNuZ1JIaUg4czdhZlA2VDVIallROFFuNmZXcnNzS1d3Vm0wS0tLMmlFVWdkUThsRDZYdTdZV3k3WkRjaUZSMUQ3dkRKYm5ZOVBjMVVBdTRjYQ?oc=5", "source_name": "Market source", "published_at": "2026-03-12T07:00:00+00:00", "published_display": "12 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q4 Earnings: Enovis (NYSE:ENOV) In The Context Of Other Medical Devices & Supplies - Specialty Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxNMzBPcXU1cnZKekZnaGlNVk05ZWFTWThNOS0tTlpvQjdaLVZIWlVXUk50NnVoQ0pPWWJpZUpWcVJyVDJMd2RJREVDbEEzTlU5UGhBbWtxWVEyVkdaMTVuNXZpaWFMNTZUQ2d0OW9Rc29kalJRY21naWlHZDBLS3RuZV9wdTdIUQ?oc=5", "source_name": "Market source", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highs And Lows: Baxter (NYSE:BAX) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxOb3BiQVNFREdNblk2QS10b1lhRUtfb05vU2VFZHB5V0hJT0R4NmhwQWRrcFVsR3UwMjZleFV6N2FEelpZVzY3YWFxSWE1cWpLaTFrQVU4NktkQUloUkxaV3ZTVkh6b1ZmaDdMN2ViX1BUNE4xUTNUZFNlR0syVGlZSg?oc=5", "source_name": "Market source", "published_at": "2026-03-02T08:00:00+00:00", "published_display": "02 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Vivos Therapeutics, Inc. (NASDAQ:VVOS) Stock Rockets 60% As Investors Are Less Pessimistic Than Expected", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-07-02T07:00:00+00:00", "published_display": "02 Jul 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivos Therapeutics (VVOS) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE5JVXFZbUExOWI5anJDcm10RU52bGYyeTduMGpOWHdLMTYwbl9ianNrcGxzcThXRG9SQUVrZjl0SnRhY0dZMTQzY3c5M3loNHdVbC1v?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-24T18:12:05+00:00", "published_display": "24 Apr 2025 18:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Investor group takes 19.9% position in Vivos Therapeutics (VVOS)", "summary": "An investor group, including V-CO Investors LLC and Michael C. Skaff, has reported a 19.9% beneficial ownership stake in Vivos Therapeutics, Inc. (VVOS), totaling 2,783,102 common shares. This position stems from a $1.6 million subscription by V-Co 4, which included the conversio", "url": "https://www.stocktitan.net/sec-filings/VVOS/schedule-13d-vivos-therapeutics-inc-major-shareholder-acquisition-5-e81518d2dc47.html", "source_name": "Stock Titan", "published_at": "2026-07-16T21:20:29", "published_display": "16 Jul 2026 21:20", "sentiment": "positive", "sentiment_pct": 61, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivos Therapeutics (NASDAQ: VVOS) insider entity buys 5.5M derivatives", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxOOC1oVWtGeWJkSzhVaWlNa0ZGeEZJWXRvTGZZVDRINms0SjJoOG1RLWpuUmU5V0dCTFNmUG5MS0VDWDN4dHpqZ0czZmNQeDRaOF9vYjcyem5BNXcydHduX2dSa0c0YS1zMVdMTWlla21TM3dXcTA5M2xRTHVBeWUzTl9lYlNITzVsVmdkZG0xZllDWUhaRVZWZ2MyUXR2cTVYdTY2eG52VGNsMGtrM3NqR2ZJYWJjTkU?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-15T20:24:16+00:00", "published_display": "15 Jul 2026 20:24", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Michael C. Skaff Discloses Investment at Vivos Therapeutics with 19.9% Stake", "summary": "Michael C. Skaff, through SP Manager LLC and its V-Co investment vehicles, has disclosed a 19.9% beneficial ownership stake in Vivos Therapeutics, Inc. This investment, formalized in a Schedule 13D filing, stems from a private placement in June 2026 that included convertible pref", "url": "https://www.tradingview.com/news/tradingview:0b986cf523702:0-michael-c-skaff-discloses-investment-at-vivos-therapeutics-with-19-9-stake/", "source_name": "TradingView", "published_at": "2026-07-15T21:20:29", "published_display": "15 Jul 2026 21:20", "sentiment": "positive", "sentiment_pct": 60, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivos Therapeutics (NASDAQ: VVOS) holder discloses warrant and preferred stake", "summary": "V-Co Investors 4 LLC, a 10% owner of Vivos Therapeutics (NASDAQ: VVOS), has disclosed its initial beneficial ownership of a Common Stock Purchase Warrant and Series A Convertible Preferred Stock. Both securities are convertible into 2,749,330 common shares at an exercise/conversi", "url": "https://www.stocktitan.net/sec-filings/VVOS/form-3-vivos-therapeutics-inc-initial-statement-of-beneficial-ownersh-e03df6f8681e.html", "source_name": "Stock Titan", "published_at": "2026-07-15T20:20:29", "published_display": "15 Jul 2026 20:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Vivos Therapeutics Inc For: 15 July By Investing.com", "summary": "This article from Investing.com reports on a Form 4 filing for Vivos Therapeutics Inc on July 15. Form 4 filings disclose changes in beneficial ownership of a company's securities by insiders. The article provides the title and source, indicating it's a routine financial disclosu", "url": "https://ca.investing.com/news/stock-market-news/form-4-vivos-therapeuticsinc-for-15-july-93CH-4736099", "source_name": "Investing.com Canada", "published_at": "2026-07-15T20:20:29", "published_display": "15 Jul 2026 20:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivos Therapeutics Inc. (VVOS) Stock Price | Live Quotes & Charts | NASDAQ", "summary": "This page provides live quotes and charts for Vivos Therapeutics Inc. (VVOS), currently trading at $0.4178 with a slight decrease. It notes that there are no current analyst ratings or earnings information available for the company. The page is part of a trading education platfor", "url": "https://www.timothysykes.com/quote/VVOS/", "source_name": "www.timothysykes.com", "published_at": "2026-07-15T00:20:29", "published_display": "15 Jul 2026 00:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Vivos Therapeutics, Inc. \u2013 NASDAQ:VVOS", "summary": "This article displays financial information for Vivos Therapeutics, Inc. (NASDAQ: VVOS), specifically focusing on its price-to-earnings forward ratio. The content appears to be a stub or a section of a larger financial data platform, showing basic company identification and navig", "url": "https://www.tradingview.com/symbols/NASDAQ-VVOS/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-09T23:39:30", "published_display": "09 Jul 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivos Therapeutics Raises $2.1 Million in PIPE With V-Co 4 and Bigger Capital", "summary": "Vivos Therapeutics completed a $2.1 million private placement (PIPE) with V-Co Investors 4 and Bigger Capital Fund, involving Series A Convertible Preferred Stock and warrants. The company received $1.0 million in cash, with another $1.0 million from a converted bridge note. Vivo", "url": "https://www.tradingview.com/news/tradingview:26dcce57228c3:0-vivos-therapeutics-raises-2-1-million-in-pipe-with-v-co-4-and-bigger-capital/", "source_name": "TradingView", "published_at": "2026-07-08T10:39:18", "published_display": "08 Jul 2026 10:39", "sentiment": "positive", "sentiment_pct": 73, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivos Therapeutics (VVOS) completes $2.1M PIPE with preferred stock and warrants", "summary": "Vivos Therapeutics completed a private PIPE financing on June 30, 2026, raising approximately $2.1 million. The financing involved selling units consisting of Series A Convertible Preferred Stock, five-year warrants at an exercise price of $0.456, and contingent subscription righ", "url": "https://www.stocktitan.net/sec-filings/VVOS/8-k-vivos-therapeutics-inc-reports-material-event-1be228ee9bc9.html", "source_name": "Stock Titan", "published_at": "2026-07-07T21:30:28", "published_display": "07 Jul 2026 21:30", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VVOS - Vivos Therapeutics Inc Latest SEC Filings", "summary": "This article provides the latest SEC filing information for Vivos Therapeutics Inc (VVOS). It includes key financial metrics such as market cap, enterprise value, income, sales, and various ratios. The data also covers stock performance, insider and institutional ownership, and a", "url": "https://finviz.com/stock?t=VVOS&ta=1&p=w&ty=lf&page=5", "source_name": "Finviz", "published_at": "2026-07-06T10:10:39", "published_display": "06 Jul 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Vivos Therapeutics, Inc. \u2013 NASDAQ:VVOS", "summary": "The article focuses on the enterprise value to EBITDA forward for Vivos Therapeutics, Inc. (NASDAQ:VVOS). It appears to be a financial data point presented within the TradingView platform for the company's NASDAQ listing.", "url": "https://www.tradingview.com/symbols/NASDAQ-VVOS/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T04:40:27", "published_display": "06 Jul 2026 04:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivos Therapeutics (VVOS) Stock Sees Fair Value Moves Lower As Analysts Reset Growth Assumptions", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxNNVVpQW1DWTczb3YtNFgwV09ReWdfQk4td09zV2xCY1hTc1hFVER3NEdDVzh5MlFzZnFGQnNNaGJ3RmhFVndQUGlYZ1hNdWxQMzdtRkNhT1VWeW5iTTJJSGJsbzFBSkc1UWFTVVIwUGtHeW1mYk5LR2pCeWlZOURSX2dDRm1oeVpJQ01UY2IyQW1JRy0tZHRrVEQxZU94bjc3?oc=5", "source_name": "Market source", "published_at": "2026-07-03T07:00:00+00:00", "published_display": "03 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "12 Health Care Stocks Moving In Tuesday's After-Market Session", "summary": "This article lists 12 healthcare stocks that experienced significant movement in Tuesday's after-market trading session. It details both gainers and losers, including Alzamend Neuro, Vivos Therapeutics, Advanced Biomed, Aclaris Therapeutics, NexGel, and Aethlon Medical as gainers", "url": "https://www.benzinga.com/trading-ideas/movers/26/06/60205064/12-health-care-stocks-moving-tuesday-s-after-market-session", "source_name": "Benzinga", "published_at": "2026-07-01T07:39:20", "published_display": "01 Jul 2026 07:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivos says its Vida appliance improved insomnia in all 37 patients", "summary": "Vivos Therapeutics announced compelling clinical data for its FDA-cleared Vida\u00ae oral appliance, showing statistically significant improvement in insomnia severity in all 37 study participants. The appliance, which reduced Insomnia Severity Index scores by an average of 65%, is al", "url": "https://www.stocktitan.net/news/VVOS/vivos-vida-appliance-shows-statistically-significant-improvement-in-h3s2rd7co3f4.html", "source_name": "Stock Titan", "published_at": "2026-06-30T20:39:57", "published_display": "30 Jun 2026 20:39", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivos\u2019 Vida\u00ae Appliance Shows Statistically Significant Improvement in Insomnia Severity in 100% of Study Participants", "summary": "Vivos Therapeutics announced that its FDA-cleared Vida\u00ae oral appliance demonstrated statistically significant improvement in insomnia severity for 100% of participants in a recent clinical study. The study, involving 37 adult patients with moderate to severe insomnia, showed an a", "url": "https://sg.finance.yahoo.com/news/vivos-vida-appliance-shows-statistically-124500026.html", "source_name": "Market source", "published_at": "2026-06-30T13:10:58", "published_display": "30 Jun 2026 13:10", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivos Therapeutics, Inc. Actuals & Estimates (NASDAQ:VVOS)", "summary": "This article provides an overview of Vivos Therapeutics, Inc. (NASDAQ:VVOS) stock performance, financial data, and analyst estimates. Key figures include the current stock price, recent declines, future price forecasts from analysts, historical highs and lows, market capitalizati", "url": "https://www.tradingview.com/symbols/NASDAQ-VVOS/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T00:10:27", "published_display": "26 Jun 2026 00:10", "sentiment": "negative", "sentiment_pct": 38, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivos (NASDAQ: VVOS) extends Streeterville $4.5M debt-for-equity pact", "summary": "Vivos Therapeutics has extended its debt-for-equity agreement with Streeterville Capital, pushing the deadline for a $2.6 million equity financing to August 31, 2026. This extension gives Vivos more time to raise capital, with Streeterville reaffirming its commitment to convert u", "url": "https://www.stocktitan.net/sec-filings/VVOS/8-k-vivos-therapeutics-inc-reports-material-event-a3c265231026.html", "source_name": "Stock Titan", "published_at": "2026-06-25T21:10:25", "published_display": "25 Jun 2026 21:10", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivos Therapeutics Enters Debt-for-Equity Deal, Extends $2.6M Financing Deadline With Streeterville", "summary": "Vivos Therapeutics has entered into a debt-for-equity Exchange Agreement with Streeterville Capital to convert debt into stock, aiming to reduce leverage and improve liquidity. Additionally, the deadline for completing a $2.6 million financing was extended to August 31, 2026, pro", "url": "https://www.tradingview.com/news/tradingview:392a2bbaa4f3f:0-vivos-therapeutics-enters-debt-for-equity-deal-extends-2-6m-financing-deadline-with-streeterville/", "source_name": "TradingView", "published_at": "2026-06-25T21:10:25", "published_display": "25 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VVOS Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for Vivos Therapeutics, Inc. (VVOS) stock, including analyst ratings, historical performance, and financial data. It indicates a significant decrease in stock price over the past year and presents analyst price estimates for the f", "url": "https://www.tradingview.com/symbols/NASDAQ-VVOS/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T16:10:26", "published_display": "25 Jun 2026 16:10", "sentiment": "negative", "sentiment_pct": 37, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivos Therapeutics and Streeterville Extend Timeframe of Strategic Financing Agreement and Reaffirm Commitment to Convert Debt Into Common Stock and Perpetual Preferred Equity", "summary": "Vivos Therapeutics and Streeterville Capital, LLC have extended their strategic financing agreement through August 31, 2026. This extension allows Vivos Therapeutics more time to complete its capital-raising requirements. Streeterville reaffirmed its commitment to convert up to $", "url": "https://finance.yahoo.com/healthcare/articles/vivos-therapeutics-streeterville-extend-timeframe-123000802.html", "source_name": "Market source", "published_at": "2026-06-25T12:40:54", "published_display": "25 Jun 2026 12:40", "sentiment": "positive", "sentiment_pct": 62, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Vivos Therapeutics and Streeterville Extend Timeframe of Strategic Financing Agreement and Reaffirm Commitment to Convert Debt Into Common Stock and Perpetual Preferred Equity", "summary": "Vivos Therapeutics and Streeterville Capital have extended the timeframe of their strategic financing agreement. This extension reaffirms their commitment to converting Streeterville's existing debt into Vivos common stock and perpetual preferred equity. The agreement aims to sig", "url": "https://www.moomoo.com/hans/news/post/71829847/press-release-vivos-therapeutics-and-streeterville-extend-timeframe-of-strategic?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-06-23T05:10:25", "published_display": "23 Jun 2026 05:10", "sentiment": "positive", "sentiment_pct": 64, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivos Therapeutics Extends Financing Agreement With Streeterville Through August", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/vivos-therapeutics-extends-financing-agreement-132301980.html", "source_name": "MT Newswires", "published_at": "2026-06-22T13:23:01+00:00", "published_display": "22 Jun 2026 13:23", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivos extends debt conversion deadline with Streeterville to August", "summary": "Vivos Therapeutics Inc. has extended its debt conversion agreement with Streeterville Capital, LLC until August 31, 2026. This extension allows Vivos more time to raise $2.6 million in equity, after which Streeterville will convert up to $4.5 million in outstanding debt into perp", "url": "https://www.investing.com/news/company-news/vivos-extends-debt-conversion-deadline-with-streeterville-to-august-93CH-4752742", "source_name": "Investing.com", "published_at": "2026-06-22T12:41:00", "published_display": "22 Jun 2026 12:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivos extends debt conversion deadline with Streeterville to August By Investing.com", "summary": "Vivos Therapeutics Inc. has extended its debt conversion deadline with Streeterville Capital, LLC to August 31, 2026. This extension allows Vivos more time to complete a planned equity raise and rights offering, aiming to strengthen its stockholders' equity and maintain Nasdaq li", "url": "https://ca.investing.com/news/stock-market-news/vivos-extends-debt-conversion-deadline-with-streeterville-to-august-93CH-4700882", "source_name": "Investing.com Canada", "published_at": "2026-06-22T12:40:27", "published_display": "22 Jun 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivos gets more time to convert $4.5M debt into equity", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxORnFvTHJCb2ZtX1pRS2pMc0U4Ql9paWdkWFM2SlhCa1lFM0RNU1Q4X0VJZW1HbDlXYUthRE11V2RZMXQ0bTJJVWM4RHhOejBqamtUelVFeGZCNWpPM1k1dU16YnRfUmtUVHZoWnBEbzJVSUt5cWJnY3VvMFl3aE91OG1MdzM4eFlhRy0ybzNFeUs5OXByUGcwX1lrM2tpSHhpdi03ajQ3cWdBZ1dZYl95eHdzVnhDZjROV19uMEhB?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivos Therapeutics Inc (VVOS) Institutional Confidence", "summary": "This article from TradingKey provides an overview of institutional confidence in Vivos Therapeutics Inc (VVOS). It presents a table of institutional shareholdings, detailing the number of shares held by various entities like V-CO Investors, L.L.C. and Armistice Capital LLC, and h", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-vvos/sentiment", "source_name": "TradingKey", "published_at": "2026-06-19T06:10:44", "published_display": "19 Jun 2026 06:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivos Therapeutics Inc (VVOS) Valuation: PE, PB & Fair Value Analysis", "summary": "Vivos Therapeutics Inc (VVOS) currently holds a valuation score of 9.29, placing it 23rd out of 203 companies in the Healthcare Equipment & Supplies industry. The company's P/E ratio is -0.23, which is significantly below its recent high and above its recent low. However, key val", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-vvos/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-19T06:10:44", "published_display": "19 Jun 2026 06:10", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivos Therapeutics Inc (VVOS) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "The article provides a historical overview of dividend payouts and stock splits for Vivos Therapeutics Inc (VVOS). It indicates that the company has distributed no dividends over the past five years and details multiple 25-to-1 merger-related stock splits that occurred on October", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-vvos/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T17:09:33", "published_display": "18 Jun 2026 17:09", "sentiment": "negative", "sentiment_pct": 41, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivos Therapeutics Inc (VVOS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a detailed revenue breakdown for Vivos Therapeutics Inc (VVOS) as of April 6, covering its business segments. Key revenue contributors include sleep testing services, appliance sales to integrated providers, and center revenue. The data presented reflects fi", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-vvos/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T16:09:33", "published_display": "18 Jun 2026 16:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivos Therapeutics (NASDAQ: VVOS) outlines proposed tradable rights offering terms", "summary": "Vivos Therapeutics plans a tradable rights offering to raise capital for operations, intending to distribute transferable subscription rights to shareholders as a dividend. The proposed terms indicate an initial exercise price for common shares at the greater of $1.25 or 20% abov", "url": "https://www.stocktitan.net/sec-filings/VVOS/8-k-vivos-therapeutics-inc-reports-material-event-f09acd67f14c.html", "source_name": "Stock Titan", "published_at": "2026-06-16T21:09:57", "published_display": "16 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivos Therapeutics Partners with Florida Cardiology Group to Expand Sleep Apnea and Insomnia Treatment for Cardiovascular Patients", "summary": "Vivos Therapeutics, Inc. has announced a strategic collaboration with South Palm Cardiovascular Associates, a multi-location Florida cardiology practice, to form AIM Florida, LLC. This partnership aims to integrate diagnostic and therapeutic clinical treatment services for cardio", "url": "https://www.minichart.com.sg/2026/06/16/vivos-therapeutics-partners-with-florida-cardiology-group-to-expand-sleep-apnea-and-insomnia-treatment-for-cardiovascular-patients/", "source_name": "Minichart", "published_at": "2026-06-16T12:10:00", "published_display": "16 Jun 2026 12:10", "sentiment": "positive", "sentiment_pct": 77, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivos Therapeutics (NASDAQ: VVOS) inks AIM Florida deal with major cardiology group", "summary": "Vivos Therapeutics (NASDAQ: VVOS) has partnered with South Palm Cardiovascular Associates (SPCVA) to establish AIM Florida, a management services organization focused on providing sleep apnea and insomnia care to cardiovascular patients in Florida. Vivos expects to hold at least ", "url": "https://www.stocktitan.net/sec-filings/VVOS/8-k-vivos-therapeutics-inc-reports-material-event-3a8dfac892b7.html", "source_name": "Stock Titan", "published_at": "2026-06-16T00:09:30", "published_display": "16 Jun 2026 00:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivos Therapeutics Plans to File for Proposed Rights Offering", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/vivos-therapeutics-plans-file-proposed-131126815.html", "source_name": "MT Newswires", "published_at": "2026-06-11T13:11:26+00:00", "published_display": "11 Jun 2026 13:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivos Therapeutics Announces Intent to File a Registration Statement for a Proposed Rights Offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQMERQMHJYeFhWS1ItSHhRcUxWeHhSTzF0aXZTQjFUbjNkLWtybHVQSlA4Vzh3bGFxOHdmbEVoN3dSMjlGNEdSazFBRWJoWUJQNDhoeFYxaGUwSUFsS0lNaUJEWV9mQW1rQ0ZjdENEejJWeUVuTGlNYUp4VXpnWmYxQlM2S2tESUk5WWNjNE5Uc3cwVXBwRndkdXBFcThCeDFqLUxhaVd1X1U?oc=5", "source_name": "Market source", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivos Therapeutics Enters Collaboration With Florida Firm to Treat Cardiovascular Patients", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/vivos-therapeutics-enters-collaboration-florida-133851968.html", "source_name": "MT Newswires", "published_at": "2026-06-10T13:38:51+00:00", "published_display": "10 Jun 2026 13:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivos Therapeutics Announces Key Collaboration Agreement with Multi-Location Florida Cardiology Group to Extend Much Needed Sleep Apnea and Insomnia Diagnosis and Treatment to Cardiovascular Patients", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/vivos-therapeutics-announces-key-collaboration-130300275.html", "source_name": "GlobeNewswire", "published_at": "2026-06-10T13:03:00+00:00", "published_display": "10 Jun 2026 13:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivos Therapeutics To Participate in the Small Cap Showcase & WTR Insights on June 9, 2026", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/vivos-therapeutics-participate-small-cap-173900683.html", "source_name": "GlobeNewswire", "published_at": "2026-06-08T17:39:00+00:00", "published_display": "08 Jun 2026 17:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sleep apnea-focused Vivos CEO to present at NYC investor forum", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxNUTlHeU1HMVhxdHV2bld5cUJGZm10VXpCb3hDaDFTM3U4aHBBMnFpUlYxeFJYNm5laTJXc0I3OTJNXzJaS3RLMkJpQm56VVpTVjZyS3RQMUItRlhZamN6b0hacUVMdVBpWnQyWkxYeElpQTBseU9iYVVLcHltdy1mX3h1SGxBZTNwSGRRM2JaQ0xGbWdDclB6OThvRVpCMmM3LVV1eS1vRWVuampkVzZEUC1sNTc1WUJUNEE?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivos grows on sleep apnea services, but operating loss hits $19.9M", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxOdFlVeUJmS2ZsaWYzTXJsOEZOd2VlWFByM0lZdFZxaERhZjBBeHFkSEN6Tmh5RmVTcGhxeE9rb3JWOWJzX01qS25vV2dDSTRNdHpHdW9KZFJZZlU1UHh2R1dfb1RNQkdxV2dfLVZ2RS1RTkVTRVlkd1dVYWoxN2JmQ2lLSmREWnpjb3loT2VKbVJlMzJVa0ZSdDh1TGRkZ1FHZkdwWVI3eWtRZw?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-15T07:00:00+00:00", "published_display": "15 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivos Therapeutics, Inc. (NASDAQ:VVOS) Stock Rockets 60% As Investors Are Less Pessimistic Than Expected", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-07-02T07:00:00+00:00", "published_display": "02 Jul 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivos Therapeutics (VVOS) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE5JVXFZbUExOWI5anJDcm10RU52bGYyeTduMGpOWHdLMTYwbl9ianNrcGxzcThXRG9SQUVrZjl0SnRhY0dZMTQzY3c5M3loNHdVbC1v?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-24T18:12:05+00:00", "published_display": "24 Apr 2025 18:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Reflecting On Medical Devices & Supplies - Specialty Stocks\u2019 Q1 Earnings: Integer Holdings (NYSE:ITGR)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNUFd1SUpRcWlCdEFjU1YzNTZkdjBfRkwyY2lBYjh1ZXZlZTlyVlpWSWx1bExvckFrNHNhUEdVTGNFWUxaMkVDZUV2c2hPS1h2YVhNSHNsVzFYNUFrNHBnRVM1STRsa2Zmb0VXeEQ4UFRGNDBOWXZfWVU5VFUyQ3JZZm9KamZMWXVDSEtNMWwyVktpaEZfRjVNU1BYaWJ3NnpNUmRyMEpsSzBXdw?oc=5", "source_name": "Market source", "published_at": "2026-07-14T18:07:11+00:00", "published_display": "14 Jul 2026 18:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks Q1 Earnings: ICU Medical (NASDAQ:ICUI) Firing on All Cylinders", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAJBVV95cUxQLWl0NWl5MFJhUXFSN0pzSW1sVzJVb21XVml0X0doQnd5eDVUQmVqeFZWSmNmdlZaV2pfbFk3UEl3RXlqZ05pckozR0dnNHNEUlpTa2FPYWc1Z3Q0Y2tXYTljZUlQRkVZNzY2Sl9yRksyUDJkNVQzSTBuLW9uMnI5bzBfTTJGdDUzd25DN3dDSmhwWnpGVXZRVVM2Uy1zMnp4STZ1RGdZZkRpZ21Pb2xtWjRSTk1kc2JrT28wTG81NDV1M2tWaVdrOXBQdVZSTExiTVEzMXpqRnJWWi0xcEdMYVFILXZXbXZVZl9GRm12aTl5OGk4X1dSVjVyU2FIVFpubk1YNm5fQll0MVZqRTZpTA?oc=5", "source_name": "StockStory", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q1 Earnings Review: Medical Devices & Supplies - Diversified Stocks Led by Baxter (NYSE:BAX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNYjhBT3BjMWFVU1FFUUFub0d6QUVEUTdwWFVMRG5fN2dHSnIxTXQwMWU1aElKaEV1a2dYLTFHMlBzMVFTZEtaX0xRRDFhZDl1WFdDYWF2RDZxOG9SRUtycmZacTRzM2FaaEU3OS1GZ2taLWtSMjZ4enhVNHRvdzJsanp4cEhNcGI1dllTOUplWUUtNjRlRm85MlFEVWxSYUV2d243QVd3?oc=5", "source_name": "Market source", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Medical Devices & Supplies - Specialty Q4 Earnings: Globus Medical (NYSE:GMED) is the Best in the Biz", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNcDFMNmtOVk5PVFM1YzMyVWhyS3dwY0dMVE5BUng5U1JoOFRQMXNFRGxTMmlBRUV0bENRSWFXTDFZOXBQQkNZT0FOWDdISjRCcU9pRV9aNHBwUVBuZkVEV3g1dklVY19KOE9iWUNpNUtMS2NuOEcxMlQtNU8ydURybEdkNVoxZThWLTBIeVhid2NjQ0FWWTUzb2dxcmlMQThFQmZ4bldzRjcwUQ?oc=5", "source_name": "Market source", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Medical Devices & Supplies - Imaging, Diagnostics Stocks\u2019 Q4 Earnings: Hologic (NASDAQ:HOLX) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOdkl6Ym5HSGVhZUw3TzNlNVFPSjdDQk5NMTVSRW1xVnh3RE5RNU9veVR0TDEtcVdxV3BYelI0bWxCYXgwWmhZQ3ZONUVRdlhjX0ZiMklRVDJQRXN0LXcyVWVnb0E2WTdiRERtZk1pNGpmVHhWbHl5eHJuNnBtTDVPMUluTmRsQUVqYjNlSl8zR3djclh0X2ZIc1gzTlhPanR6ZTJ6R1FB?oc=5", "source_name": "Market source", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Artivion (NYSE:AORT) Vs The Rest Of The Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPaTgxS3dlMlZ5dDZ3dFlGdG9yRWFubkVqMk9yOTN6OEtyemljTWJGYUcxb2pmd2FTNTFKMlhIVGxrdlJsOG5iY1VQaXE4ZmYycTVpRkE0aEJ3QlB5bC10ZXN2dTFYNy0wRWdrNURVUlo5dEMzQklxQ0kwQTRkOXE0UDdTMkRGRWxoQ1ZQeG4tOXNONlR2SkxfZW5ST1B6N3BBeFZZQ3N1UFE?oc=5", "source_name": "Market source", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: CooperCompanies (NASDAQ:COO) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxOellVLTAtRXF1dTFacmVLUmptUVpDSkxGX0MtY2hCY2l3ajU4M25SMG95OHdlc1RHN1dmaHZZMF9uQ0o3R1FBa0NzQUtZMjIzMjU1bmttbGZsZUplQkd5Vmd2NEJoQ0NnbVhmVXppdWhiQkdpcGpQVFJVSHRBXy1pbnFJbXI0R2w3MmlvMEdCY2dGYVE4cWY2MENmeEp1ME9mZEFqSDVtdThTMk9kbUhIdXMtR0k?oc=5", "source_name": "Market source", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q4 Earnings: Integer Holdings (NYSE:ITGR) In The Context Of Other Medical Devices & Supplies - Specialty Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAJBVV95cUxNdFRrRlJvM3J3cGJnVEJ6ZndqMnQxWkE4Wm8zTGtPTVc0OTlLN1pwNXIyclNJMFZkcG5qQTRTWThmNm9WN0hKYXBja3N3Y20zSlkxc2JaQlpYTnAyWnpvUVBvR1JWNmVxZGhSYVlYQklMd01GeFBVNGJWOFBWYUkwYmRrM2xrSktiQWpfTkZtNG1HWThNT0tqLUpYek5qcnFWMGE0QV9CaElrMUpfTEhnOC1pS2t1bkE2VVJHdEhWdEtoX2xKNE1MWk1OSlBSNTVZVU83WEpnb3E4aURwQ3ZyZUFDbndpTTZEa0lZRTJvU2VuTDhreXdCQ25iV3Y4YWxENm1xYQ?oc=5", "source_name": "StockStory", "published_at": "2026-03-16T07:00:00+00:00", "published_display": "16 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highs And Lows: Abbott Laboratories (NYSE:ABT) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxPeVpVN2I3X3lJNXd3TXJmRWV4X0RvRDdYR3l5a1k1SjMxUlhsWHdrUUNuZ1JIaUg4czdhZlA2VDVIallROFFuNmZXcnNzS1d3Vm0wS0tLMmlFVWdkUThsRDZYdTdZV3k3WkRjaUZSMUQ3dkRKYm5ZOVBjMVVBdTRjYQ?oc=5", "source_name": "Market source", "published_at": "2026-03-12T07:00:00+00:00", "published_display": "12 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q4 Earnings: Enovis (NYSE:ENOV) In The Context Of Other Medical Devices & Supplies - Specialty Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxNMzBPcXU1cnZKekZnaGlNVk05ZWFTWThNOS0tTlpvQjdaLVZIWlVXUk50NnVoQ0pPWWJpZUpWcVJyVDJMd2RJREVDbEEzTlU5UGhBbWtxWVEyVkdaMTVuNXZpaWFMNTZUQ2d0OW9Rc29kalJRY21naWlHZDBLS3RuZV9wdTdIUQ?oc=5", "source_name": "Market source", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highs And Lows: Baxter (NYSE:BAX) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxOb3BiQVNFREdNblk2QS10b1lhRUtfb05vU2VFZHB5V0hJT0R4NmhwQWRrcFVsR3UwMjZleFV6N2FEelpZVzY3YWFxSWE1cWpLaTFrQVU4NktkQUloUkxaV3ZTVkh6b1ZmaDdMN2ViX1BUNE4xUTNUZFNlR0syVGlZSg?oc=5", "source_name": "Market source", "published_at": "2026-03-02T08:00:00+00:00", "published_display": "02 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 84, "total_relevant": 52, "sentiment_summary": {"positive": 11, "negative": 6, "neutral": 35, "score": 53, "total": 52, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 76, "events": [{"event": "general", "label": "Market update", "weight": 12.1, "count": 22}, {"event": "earnings", "label": "Earnings", "weight": 6.19, "count": 14}, {"event": "liquidity", "label": "Balance sheet", "weight": 3.85, "count": 7}, {"event": "deals", "label": "Deals and strategy", "weight": 2.75, "count": 5}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}], "positive_events": 11, "negative_events": 6}, "market_context": {"has_market_context": true, "latest_close": 0.43, "latest_week": "2026-07-10", "one_week_move": -4.7, "four_week_move": -24.5, "twelve_week_move": -55.7, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.174623, "market_dynamics_buy_signal": false, "relative_strength": -83.461952, "fair_value_gap": -88.3, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 37.7953, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-4.7% over one week, -24.5% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 60, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 13}, {"label": "Stock Titan", "count": 12}, {"label": "TradingView", "count": 7}, {"label": "TradingKey", "count": 4}, {"label": "MT Newswires", "count": 3}, {"label": "Investing.com Canada", "count": 2}, {"label": "StockStory", "count": 2}, {"label": "GlobeNewswire", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 41}, {"label": "Industry context", "count": 11}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 22}, {"label": "Earnings", "count": 14}, {"label": "Balance sheet", "count": 7}, {"label": "Deals and strategy", "count": 5}, {"label": "Analyst action", "count": 2}, {"label": "Capital return", "count": 1}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "53/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "76/100 classification confidence."}, {"label": "Company focus", "value": "41", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-4.7% over one week, -24.5% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Investor group takes 19.9% position in Vivos Therapeutics (VVOS)"}], "updated_at": "2026-07-17T13:48:18.380068+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}